Dr Reddy's Laboratories Ltd

The revenue growth was broad-based across key markets, except for North America Generics which reported a decline primarily on account of lower Lenalidomide sales. Growth was further aided by favourable foreign exchange rate movements. Profit before tax (PBT) dropped 17.68% YoY to Rs 1,542.9 crore during the quarter. EBITDA stood at Rs 2,049.3 crore, registering de-growth of 12.84% compared with Rs 2351.1 crore posted in corresponding quarter last year. EBITDA margin reduced to 23.5% in Q3 FY26 as against 26.7% in Q3 FY25. Revenue from global generics increased 7% YoY to Rs 7,911.3 crore during the quarter. In Q3 FY26, revenue from North America declined 20% YoY to Rs 2,964.4 crore, primarily due to lower Lenalidomide sales and higher price erosion in certain key products. The North America region accounted for 34% of total revenue during the quarter. Revenue from Europe region increased 20% YoY to Rs 1447.6 crore during the quarter, supported by new generic product launches, growth witnessed in the nicotine replacement therapy (NRT) portfolio and favourable forex movements. These positives were partly offset by pricing pressure in generics. Revenue from India jumped 19% YoY to Rs 1,603.2 crore in Q3 FY26, driven by strong performance of the innovation portfolio, new brand launches, price increases, higher volumes, and contributions from the recently acquired Stugeron portfolio. India contributed 18% of total revenue during the quarter. Revenue from emerging markets surged 32% YoY to Rs 1896.1 crore, largely driven by new product launches across markets, aided by favourable forex. R&D Expenses stood at Rs 614.9 crore during the quarter, registering a 8% YoY decline due to reduced development spending in biosimilars following completion of a large part of the investments related to Abatacept. R&D spends remain focused on complex generics, biosimilars, peptides and novel biologics. The quarter's R&D spend also included a one-time provision related to new labour codes. Excluding this one-off item, R&D expenditure stood at 6.8% of revenues for the quarter. Co-chairman & MD, G V Prasad said: Our growth in Q3FY26 was supported by continued momentum in our branded businesses, aided by favourable forex, thus offsetting the impact of lower Lenalidomide sales. We continue to focus on disciplined execution of our strategic priorities of base business growth, pipeline advancement, operational efficiencies, and select inorganic opportunities, to create long-term value for our stakeholders. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The scrip rallied 4.48% to Rs 1207.30 on the BSE.Powered by Capital Market - Live

Net profit of Dr Reddy's Laboratories declined 14.42% to Rs 1209.90 crore in the quarter ended December 2025 as against Rs 1413.70 crore during the previous quarter ended December 2024. Sales rose 4.41% to Rs 8727.00 crore in the quarter ended December 2025 as against Rs 8358.60 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales8727.008358.60 4 OPM %21.6327.19 - PBDT2064.202345.70 -12 PBT1543.201874.30 -18 NP1209.901413.70 -14 Powered by Capital Market - Live

Dr. Reddy's Laboratories announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra Strength Pataday' Once-Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an Antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. Powered by Capital Market - Live

AVT03 is a proposed biosimilar to Amgen's Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech's manufacturing facility in Reykjavik, Iceland. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company's consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25. The counter slipped 1.66% to Rs 1,250 on the BSE. Powered by Capital Market - Live

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 21 January 2026.Powered by Capital Market - Live

Dr Reddys Laboratories has allotted 9,165 equity shares under ESOS on 09 December 2025. Powered by Capital Market - Live

Eftilagimod alfa is a novel immunotherapy with the potential to set a new standard of care in combination with anti-PD- (L)1 and chemotherapy as first-line therapy for non-small cell lung cancer. Eftilagimod Alfa's broad potential extends to other major cancers across multiple stages of disease. Under the terms, Immutep to receive upfront payment of $20 million (around AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestones payments of up to $349.5 million approximately AUD 528.4 million), plus double-digit royalties on commercial sales. Under the terms of the agreement, Immutep grants Dr. Reddy's an exclusive license, with the right to grant sublicense to develop, register and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. The company aims to leverage its scientific capabilities and extensive market reach to drive the development and commercialization of the cancer therapy across multiple global markets. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company's consolidated net profit jumped 7.3% to Rs 1,347.10 crore on 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25. The counter shed 0.76% to Rs 1,265.30 on the BSE.Powered by Capital Market - Live

Dr Reddys Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 1258.9, up 0.01% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.15% on the day, quoting at 26164.95. The Sensex is at 85592.35, down 0.13%. Dr Reddys Laboratories Ltd has added around 5.26% in last one month. Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 1.94% in last one month and is currently quoting at 22998.3, down 0.52% on the day. The volume in the stock stood at 9.23 lakh shares today, compared to the daily average of 16.06 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 1263.2, down 0.14% on the day. Dr Reddys Laboratories Ltd is up 3.04% in last one year as compared to a 7.78% gain in NIFTY and a 1.9% gain in the Nifty Pharma index.The PE of the stock is 19.45 based on TTM earnings ending September 25.Powered by Capital Market - Live

AVT03 is a human monoclonal IgG2 antibody and biosimilar candidate to Prolia and Xgeva, which are both denosumab but in different presentations. Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures, bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term treatment with systemic glucocorticoid. Xgeva is a prescription medicine used to prevent bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone. The EC decision is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway. In May 2024, Dr. Reddy's and Alvotech entered into a license and supply agreement for the commercialization of AVT03. Under the agreement, Alvotech will develop and manufacture AVT03, while Dr. Reddy's is responsible for registration and commercialization in applicable markets, including the U.S. and Europe. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company's consolidated net profit jumped 7.3% to Rs 1,347.10 crore on 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.Powered by Capital Market - Live

Dr Reddys Laboratories announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia' (denosumab) and Xgeva' (denosumab). Prolia' is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures, bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term treatment with systemic glucocorticoid. Xgeva' is a prescription medicine used to prevent bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone. The EC decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) adopted in September 2025 and was based on a totality of evidence, including analytical comparisons, pharmacokinetic and pharmacodynamic data, and outcomes from a confirmatory clinical trial. The EC decision is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway. In May 2024, Dr. Reddy's and Alvotech entered into a license and supply agreement for the commercialization of AVT03. Under the agreement, Alvotech will develop and manufacture AVT03, while Dr. Reddy's is responsible for registration and commercialization in applicable markets, including the U.S. and Europe. Dr. Reddy's commercialization rights are exclusive for the U.S., and semi-exclusive for Europe and the UK. Upon approval Dr. Reddy's will offer the biosimilar under the tradenames Acvybra' (denosumab) 60 mg/mL solution for injection in a pre-filled syringe and Xbonzy' (denosumab) 70 mg/mL solution for injection in a vial.Powered by Capital Market - Live